pharmaphorum |
Phase III Study Shows Roche's Alecensa Improves PFS over Crizotinib in ALK-Positive NSCLC
Genetic Engineering & Biotechnology News Roche said a second Phase III study has shown that non-small-cell lung cancer (NSCLC) patients treated with its oral anaplastic lymphoma kinase (ALK) inhibitor Alecensa® (alectinib) stayed alive without their disease worsening for significantly longer ... Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial Roche's Alecensa notches trial win against Pfizer's Xalkori |
from Health - Google News http://ift.tt/2oks3h7